Applying Contamination Control By Design: A Practical Guide For CDMOs

By Kieran Falvey, Pharmalliance Consulting Ltd.

The first article in this series explained why traditional contamination control programs leave CDMOs structurally exposed to EU GMP Annex 1 scrutiny. This article shows what to do about it.

EU GMP Annex 1 (2022) requires sterile manufacturers to maintain a documented Contamination Control Strategy (CCS): a system that demonstrates contamination risk has been analyzed systematically across design decisions, process controls, human factors, and monitoring programs. For CDMOs managing multiple products through shared infrastructure, meeting that requirement demands more than updating existing SOPs.

As outlined in Part 1, Annex 1¹ is the only regulation that mandates a CCS by name, FDA expectations under the 2004 Aseptic Processing Guidance, 21 CFR 211, ICHQ9, ICHQ10 and the Pharmaceutical Inspection Cooperation Scheme² (PIC/S) are substantively equivalent. For CDMOs serving both markets, a CCS built to Annex 1 satisfies both regulators simultaneously in one document with every question answered.

The first article in this series described why CDMOs are disproportionately exposed to Annex 1's CCS requirement, why conventional contamination control programs fall structurally short, and what Contamination Control by Design³ (CCbD) is: a methodology for embedding contamination risk management at the design layer of a pharmaceutical operation, where it is most effective and most durable. The CCbD Standard, which formalizes this methodology, is available without charge at www.ccbd.io.

This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and describes what inspection-ready contamination control documentation actually looks like when a regulatory authority arrives.

The CDMO-Specific Complexity CCbD Needs To Address

CDMOs face contamination control challenges that single-product manufacturers do not encounter at the same scale. Three deserve particular attention.

Multiproduct campaign risk. When two or more products share manufacturing equipment or cleanroom space, the risk of cross-contamination must be managed not only through cleaning validation but through scheduling controls, analytical detection limits, and documented risk acceptance by each relevant client. A CCbD approach makes this risk visible at the design level, building product segregation requirements into the operational framework rather than managing them case by case.

Client audit pressure. CDMOs routinely face client audits that review the same contamination control documentation that regulatory authorities will inspect. If the CCS is a document assembled before the audit, inconsistencies appear quickly. If it is a system that reflects actual design decisions and operational controls, client auditors and regulatory inspectors encounter the same coherent picture, reducing preparation burden and audit risk simultaneously.

ATMP and low-bioburden modality expansion. CDMOs expanding into advanced therapy medicinal products (ATMPs) or low-bioburden manufacturing face contamination control requirements that differ substantially from classical sterile operations. Segregation demands, personnel qualification requirements, environmental monitoring approaches, and risk classification methods all require reconfiguration, and these cannot be addressed by adapting an existing CCS designed for a different modality. A CCbD approach, applied at the design stage of any new program, prevents the accumulation of contamination control debt that typically emerges when a new product type is onboarded without structured assessment.

Five Practical Steps To Begin Applying CCbD

Organizations do not need to rebuild their quality systems to begin applying CCbD principles. The following five steps provide a practical entry point that builds inspection-ready structure without unnecessary disruption.

1. Conduct a structured gap assessment against EU Annex 1. Map your existing contamination control documentation against the CCS requirement. Identify where design rationale is missing, where risk assessments lack facility-wide scope, and where monitoring programs are not linked to documented risk decisions.
2. Build a facility-level risk library. Organize contamination risks by zone, process step, and personnel and material flow route. This becomes the structured foundation for your CCS and provides the traceability inspectors look for between risk identification and control selection.
3. Link design decisions to risk rationale. For each significant contamination control decision, including room classification, pressure differential, gowning requirement, and equipment configuration, document the risk basis. This does not require rewriting existing SOPs; it requires adding a rationale layer that connects design choices to contamination outcomes.
4. Align your environmental monitoring program and operational procedures to your risk profile. Review sampling locations, frequencies, and alert and action limits against your current risk library, ensuring all identified risks are monitored. Review procedural controls to ensure that your end-to-end process is protected from vendor management, operator gowning, and self-inspection and governance.
5. Build CCbD into your tech transfer and new product introduction process. Every new product onboarded to a CDMO facility should trigger a structured contamination risk assessment against the existing facility risk profile, not a generic risk assessment template. This prevents contamination control debt from accumulating as the product portfolio grows.

What Inspection-Ready Contamination Control Actually Looks Like

When a regulatory inspector reviews a CDMO's contamination control program, they are not looking for a complete set of SOPs. They are looking for evidence that the organization understands its contamination risks, has designed controls that address those risks, and monitors their effectiveness consistently. The documentation that supports this picture must be coherent, traceable, and proportionate, not exhaustive.

A CCbD-structured CCS produces exactly this. It gives inspectors a single point of entry into the contamination control system that explains how the facility was designed to control contamination, what operational controls are in place, how monitoring data is reviewed, and how the system responds when controls show reduced effectiveness. Each element links to supporting documentation without requiring the inspector to assemble the picture themselves.

CDMOs that invest in this structure now, before their next inspection, before their next client audit, before their next product onboarding, will find that the investment pays for itself quickly. The cost of building contamination control into design is a fraction of the cost of retrofitting it after a warning letter, a clinical hold, or a contract loss.

The Bottom Line

Annex 1 did not create a new problem; it gave regulatory authority to a problem that already existed. CDMOs that manage multiple products through shared infrastructure have always carried a higher contamination risk profile than single-product manufacturers. What has changed is the expectation that this risk is systematically documented, proactively managed, and demonstrably in control.

Contamination Control by Design is the approach that makes this possible. It moves contamination control from a compliance function into a design discipline, embedding risk management at the level where it is most effective and most durable. The CCbD Standard, available free at www.ccbd.io, provides the structured framework for getting there. For CDMOs competing on quality, reliability, and regulatory confidence, that shift is not optional. It is the foundation on which inspection-ready operations are built.

References:

1. European Commission. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. August 2022.
2. PIC/S PE 009-17. Guide to Good Manufacturing Practice for Medicinal Products, Annex 1. Pharmaceutical Inspection Co-operation Scheme. 2023.

About The Author:

Kieran Falvey is managing director of Pharmalliance Consulting Ltd., an Irish consulting practice specializing in GMP compliance, remediation, and contamination control for sterile, non-sterile, ATMP, and CDMO manufacturers. With over two decades of experience in pharmaceutical engineering, quality, and compliance, Kieran works with manufacturers globally to design and implement inspection-ready contamination control programs aligned to FDA, EU GMP Annex 1 (2022), PDA, and ICH guidelines. He can be reached at kfalvey@pharmalliance.ie.